A phase II, randomised, double blind, placebo controlled, three way crossover study to assess the bronchodilator effect of RPL554 administered in addition to open label tiotropium in patients with COPD

Trial Profile

A phase II, randomised, double blind, placebo controlled, three way crossover study to assess the bronchodilator effect of RPL554 administered in addition to open label tiotropium in patients with COPD

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Aug 2018

At a glance

  • Drugs RPL 554 (Primary) ; Tiotropium bromide (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Sponsors Verona Pharma
  • Most Recent Events

    • 30 Aug 2018 Results of pooled data from two trials (NCT02542254 and NCT03028142), were published in the European Respiratory Journal.
    • 23 May 2018 Results presented at the 114th International Conference of the American Thoracic Society.
    • 21 May 2018 Results presented in a Verona Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top